Vaccine and Cell & Gene Therapies
Expanding Manufacturing Capacity to Meet Market Demand for Vaccines and Cell and Gene Therapeutics
lrike Fiedler Dr. Rer. Nat.
IDT Biologika
PAO-04-022-CL-02Apr 13, 2022
Viral Vectors
Smart Scale-Up: Expanding Viral Vectors With Microcarrier Bead Technology
Heidi Trusheim, Ph.D.
IDT Biologika
PAO-02-022-CL-09Mar 12, 2022
Oncolytic Viruses
Best Practices For Oncolytic Virus Design, Development, and Manufacturing
Heidi Trusheim, Ph.D.; Trevor Broadt
IDT Biologika
PAO-02-022-CL-17Mar 09, 2022
Scale-Up Collaboration
IDT Biologika Collaborates with Exothera to Push Forward the Scale-Up of Viral Vaccines
IDT Biologika
PR-M03-22-01Mar 01, 2022
Vaccines
100 Years in Vaccines and Looking Toward the Future
IDT Biologika
PAO-01-22-R250-13Jan 28, 2022
Vaccines
IDT Biologika is Increasing its Production Capacity of Vaccines – Saxony-Anhalt's Prime Minister Reiner Haseloff Visited the New Facilities
IDT Biologika
PR-M01-22-13Jan 20, 2022
2021 Roundup: The Year of Cell and Gene Therapy
David Alvaro, Ph.D.
Pharma's Almanac
PA734Dec 20, 2021
Collaboration
Valneva and IDT Biologika Announce Collaboration for Production of Inactivated COVID-19 Vaccine VLA2001
IDT Biologika
PR-M12-21-02Dec 15, 2021
Viral Vaccines
Viral Vectors, Vaccines — A New Era Of Collaborative Design
Andreas Neubert, Ph.D.
IDT Biologika
PAO-10-21-CL-17Nov 08, 2021
Vaccines
IDT Biologika Celebrates 100 Years of Successful Vaccine Development and U.S. Expansion
Ashik Pavagadhi
IDT Biologika
PAO-10-21-CL-07-793Oct 15, 2021